Even women with typically regular periods can sometimes experience minor hormonal fluctuations that lead to a late period
Pictured: Woman grasping her stomach in pain/iStock, Doucefleur The use of glucagon-like peptide 1 (GLP-1) agonists for weight loss, such as Novo Nordisks Ozempic and Wegovy, is associated with the risk of gastrointestinal adverse events, according to a study published Thursday in the medical journal JAMA
Honest Care is built to support patients navigating insurance denials, whether the appeal is submitted by the patient or by their clinician
Tips on Timing, Rotation, and Technique Figuring out the best spot to inject comes first
Other symptoms can include joint pain, frozen shoulder, depression, anxiety, irregular menstrual cycles, infertility, and even heart palpitations
This may involve: A healthcare professional will normally guide the transition to ensure treatment remains safe and effective Wegovy and Ozempic contain the same active ingredient, semaglutide, but they are approved for different uses and are prescribed at different doses